These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
191 related articles for article (PubMed ID: 33611885)
1. Ipragliflozin, an SGLT2 Inhibitor, Ameliorates High-Fat Diet-Induced Metabolic Changes by Upregulating Energy Expenditure through Activation of the AMPK/ SIRT1 Pathway. Lee JY; Lee M; Lee JY; Bae J; Shin E; Lee YH; Lee BW; Kang ES; Cha BS Diabetes Metab J; 2021 Nov; 45(6):921-932. PubMed ID: 33611885 [TBL] [Abstract][Full Text] [Related]
2. Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction. Komiya C; Tsuchiya K; Shiba K; Miyachi Y; Furuke S; Shimazu N; Yamaguchi S; Kanno K; Ogawa Y PLoS One; 2016; 11(3):e0151511. PubMed ID: 26977813 [TBL] [Abstract][Full Text] [Related]
3. Ipragliflozin improves mitochondrial abnormalities in renal tubules induced by a high-fat diet. Takagi S; Li J; Takagaki Y; Kitada M; Nitta K; Takasu T; Kanasaki K; Koya D J Diabetes Investig; 2018 Sep; 9(5):1025-1032. PubMed ID: 29352520 [TBL] [Abstract][Full Text] [Related]
4. Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice. Tahara A; Kurosaki E; Yokono M; Yamajuku D; Kihara R; Hayashizaki Y; Takasu T; Imamura M; Li Q; Tomiyama H; Kobayashi Y; Noda A; Sasamata M; Shibasaki M Eur J Pharmacol; 2013 Sep; 715(1-3):246-55. PubMed ID: 23707905 [TBL] [Abstract][Full Text] [Related]
5. SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats. Yokono M; Takasu T; Hayashizaki Y; Mitsuoka K; Kihara R; Muramatsu Y; Miyoshi S; Tahara A; Kurosaki E; Li Q; Tomiyama H; Sasamata M; Shibasaki M; Uchiyama Y Eur J Pharmacol; 2014 Mar; 727():66-74. PubMed ID: 24486393 [TBL] [Abstract][Full Text] [Related]
6. SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice. Xu L; Nagata N; Nagashimada M; Zhuge F; Ni Y; Chen G; Mayoux E; Kaneko S; Ota T EBioMedicine; 2017 Jun; 20():137-149. PubMed ID: 28579299 [TBL] [Abstract][Full Text] [Related]
7. Dietary luteolin activates browning and thermogenesis in mice through an AMPK/PGC1α pathway-mediated mechanism. Zhang X; Zhang QX; Wang X; Zhang L; Qu W; Bao B; Liu CA; Liu J Int J Obes (Lond); 2016 Dec; 40(12):1841-1849. PubMed ID: 27377953 [TBL] [Abstract][Full Text] [Related]
8. Ginger prevents obesity through regulation of energy metabolism and activation of browning in high-fat diet-induced obese mice. Wang J; Li D; Wang P; Hu X; Chen F J Nutr Biochem; 2019 Aug; 70():105-115. PubMed ID: 31200315 [TBL] [Abstract][Full Text] [Related]
9. Cardiac ischemia-reperfusion injury under insulin-resistant conditions: SGLT1 but not SGLT2 plays a compensatory protective role in diet-induced obesity. Yoshii A; Nagoshi T; Kashiwagi Y; Kimura H; Tanaka Y; Oi Y; Ito K; Yoshino T; Tanaka TD; Yoshimura M Cardiovasc Diabetol; 2019 Jul; 18(1):85. PubMed ID: 31262297 [TBL] [Abstract][Full Text] [Related]
10. Effect of quercetin on nonshivering thermogenesis of brown adipose tissue in high-fat diet-induced obese mice. Pei Y; Otieno D; Gu I; Lee SO; Parks JS; Schimmel K; Kang HW J Nutr Biochem; 2021 Feb; 88():108532. PubMed ID: 33130188 [TBL] [Abstract][Full Text] [Related]
11. SGLT2 inhibitor ipragliflozin alone and combined with pioglitazone prevents progression of nonalcoholic steatohepatitis in a type 2 diabetes rodent model. Tahara A; Takasu T Physiol Rep; 2019 Nov; 7(22):e14286. PubMed ID: 31782258 [TBL] [Abstract][Full Text] [Related]
12. Inhibition of the sodium-glucose co-transporter SGLT2 by canagliflozin ameliorates diet-induced obesity by increasing intra-adipose sympathetic innervation. Yang X; Liu Q; Li Y; Ding Y; Zhao Y; Tang Q; Wu T; Chen L; Pu S; Cheng S; Zhang J; Zhang Z; Huang Y; Li R; Zhao Y; Zou M; Shi X; Jiang W; Wang R; He J Br J Pharmacol; 2021 Apr; 178(8):1756-1771. PubMed ID: 33480065 [TBL] [Abstract][Full Text] [Related]
13. Empagliflozin reverses obesity and insulin resistance through fat browning and alternative macrophage activation in mice fed a high-fat diet. Xu L; Nagata N; Chen G; Nagashimada M; Zhuge F; Ni Y; Sakai Y; Kaneko S; Ota T BMJ Open Diabetes Res Care; 2019; 7(1):e000783. PubMed ID: 31749970 [TBL] [Abstract][Full Text] [Related]
14. Therapeutic Effects of SGLT2 Inhibitor Ipragliflozin and Metformin on NASH in Type 2 Diabetic Mice. Tahara A; Takasu T Endocr Res; 2020; 45(2):147-161. PubMed ID: 31955626 [No Abstract] [Full Text] [Related]
15. The diabetes medication canagliflozin promotes mitochondrial remodelling of adipocyte via the AMPK-Sirt1-Pgc-1α signalling pathway. Yang X; Liu Q; Li Y; Tang Q; Wu T; Chen L; Pu S; Zhao Y; Zhang G; Huang C; Zhang J; Zhang Z; Huang Y; Zou M; Shi X; Jiang W; Wang R; He J Adipocyte; 2020 Dec; 9(1):484-494. PubMed ID: 32835596 [TBL] [Abstract][Full Text] [Related]
16. 5-HEPE reduces obesity and insulin resistance by promoting adipose tissue browning through GPR119/AMPK/PGC1α activation. Zong Y; Wang M; Liu Y; Suo X; Fan G; Yang X Life Sci; 2023 Jun; 323():121703. PubMed ID: 37075946 [TBL] [Abstract][Full Text] [Related]
17. Ipragliflozin-induced improvement of liver steatosis in obese mice may involve sirtuin signaling. Suga T; Sato K; Ohyama T; Matsui S; Kobayashi T; Tojima H; Horiguchi N; Yamazaki Y; Kakizaki S; Nishikido A; Okamura T; Yamada M; Kitamura T; Uraoka T World J Hepatol; 2020 Jul; 12(7):350-362. PubMed ID: 32821334 [TBL] [Abstract][Full Text] [Related]
18. The Sodium Glucose Cotransporter 2 Inhibitor Ipragliflozin Promotes Preferential Loss of Fat Mass in Non-obese Diabetic Goto-Kakizaki Rats. Takasu T; Hayashizaki Y; Hirosumi J; Minoura H; Amino N; Kurosaki E; Takakura S Biol Pharm Bull; 2017; 40(5):675-680. PubMed ID: 28458353 [TBL] [Abstract][Full Text] [Related]
19. Seabuckthorn Reverses High-Fat-Diet-Induced Obesity and Enhances Fat Browning via Activation of AMPK/SIRT1 Pathway. Wang Y; Gao X; Chen X; Li Q; Li X; Zhao J Nutrients; 2022 Jul; 14(14):. PubMed ID: 35889860 [TBL] [Abstract][Full Text] [Related]
20. AMP-Activated Protein Kinase (AMPK) Regulates Energy Metabolism through Modulating Thermogenesis in Adipose Tissue. Wu L; Zhang L; Li B; Jiang H; Duan Y; Xie Z; Shuai L; Li J; Li J Front Physiol; 2018; 9():122. PubMed ID: 29515462 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]